Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Equity Average (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Equity Average data on record, last reported at $341.2 million in Q1 2026.

  • On a quarterly basis, Equity Average rose 44.7% to $341.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $341.2 million, a 44.7% increase, with the full-year FY2025 number at $296.0 million, up 23.8% from a year prior.
  • Equity Average reached $341.2 million in Q1 2026 per FULC's latest filing, up from $273.7 million in the prior quarter.
  • Over the last five years, Equity Average for FULC hit a ceiling of $341.2 million in Q1 2026 and a floor of $175.0 million in Q2 2022.
  • A 5-year average of $240.2 million and a median of $243.7 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 79.74% in 2022, then decreased 22.28% in 2025.
  • Tracing FULC's Equity Average over 5 years: stood at $210.2 million in 2022, then increased by 16.72% to $245.3 million in 2023, then grew by 1.97% to $250.2 million in 2024, then rose by 9.4% to $273.7 million in 2025, then increased by 24.65% to $341.2 million in 2026.
  • Business Quant data shows Equity Average for FULC at $341.2 million in Q1 2026, $273.7 million in Q4 2025, and $206.4 million in Q3 2025.